## MEDP: Medpace Holdings, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -8.4% below STRENGTH zone (4.0-10.0%); PEG 4.14 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($512.35)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Epoch Investment Partners Inc. Raises Holdings in Medpace Holdings, Inc. $MEDP**
- Source: MarketBeat | 20251206T043337 | Neutral | Relevance: 98%
-  Epoch Investment Partners Inc. increased its stake in Medpace Holdings, Inc. by 11.4%, now holding 445,231 shares valued at approximately $139.74 million. This accumulation comes despite significant insider selling totaling $233.39 million by executives within the last 90 days. Medpace (NASDAQ:MEDP) reported strong quarterly earnings, beating EPS estimates and demonstrating 23.7% year-over-year revenue growth, but analysts maintain a "Hold" rating due to its high valuation.

**2. What Makes Medpace Holdings (MEDP) an Investment Choice?**
- Source: Insider Monkey | 20251209T140513 | Bullish | Relevance: 98%
-  Giverny Capital Asset Management highlighted Medpace Holdings (MEDP) as a key investment in its Q3 2025 investor letter, despite initial concerns leading to a share drop. The firm's conviction grew as Medpace consistently communicated business stability and repurchased 9% of its shares at depressed prices, leading to a significant stock recovery. While recognizing MEDP's potential, Giverny also suggests that some AI stocks may offer even greater and quicker returns.

**3. Arrowstreet Capital Limited Partnership Grows Position in Medpace Holdings, Inc. $MEDP**
- Source: MarketBeat | 20251207T083337 | Neutral | Relevance: 98%
- Arrowstreet Capital Limited Partnership increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 25.8% in Q2, acquiring an additional 21,040 shares, bringing their total to 102,739 shares valued at $32.25 million. This increase comes despite recent insider selling by the CEO and CFO, who collectively sold shares worth over $2 million, though insiders still retain a 20.30% ownership. Medpace recently surpassed quarterly earnings and revenue estimates, prompting some analysts, like Mizuho, to raise their price targets, maintaining a consensus "Hold" rating with an average target of $487.18.

**4. 212,188 Shares in Medpace Holdings, Inc. $MEDP Acquired by Norges Bank**
- Source: MarketBeat | 20251206T043337 | Somewhat-Bullish | Relevance: 98%
-  Norges Bank acquired 212,188 shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the second quarter, representing a new stake valued at approximately $66.6 million. Despite this institutional buying, company insiders have been significant sellers, offloading shares worth over $233 million in the last three months. Medpace recently surpassed quarterly earnings expectations, and analysts currently hold a consensus "Hold" rating with a price target of $487.18.

**5. XTX Topco Ltd Sells 5,327 Shares of Medpace Holdings, Inc. $MEDP**
- Source: MarketBeat | 20251208T130949 | Neutral | Relevance: 98%
- XTX Topco Ltd significantly reduced its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 84.1% in Q2, selling 5,327 shares and retaining 1,009 shares. While institutional investors like Invesco, Mawer, and JPMorgan increased their holdings, company insiders, including CEO August J. Troendle and VP Susan E. Burwig, sold a substantial number of shares, totaling 387,925 shares valued at $233.4 million over the past 90 days. The stock currently has a "Hold" consensus rating from analysts with an average target price of $487.18.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-13 | BMO Capital | $600 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-13 | BMO Capital | init | Market Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 6 ($4.35M) |
| Sells | 27 ($204.69M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 36.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 8.4% (-4.4%)
- Vanguard Group Inc: 8.1% (-4.5%)
- AQR Capital Manageme: 3.6% (+65.1%)
- Wasatch Advisors LP: 3.3% (-2.1%)
- State Street Corpora: 2.4% (-4.8%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-4.8% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $205M sold (27 transactions in 90 days).
3. Valuation stretched: PEG 4.1x requires aggressive growth execution.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 4.14 signals overvaluation risk, limited margin of safety. Forward P/E 33.3x stretched relative to 9% growth. Quality metrics strong (ROE 74%, ROA 16%, margin 18%). Insider selling cluster ($204.7M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $15.5B |
| Beta | 1.43 |
| 52W Range | $250.05 - $626.25 |
| Short Interest | 6.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.14 |
| Forward P/E | 33.3 |
| Current P/E | 36.3 |
| YoY Growth | 9.1% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from -3.6% to -8.4% (-4.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 12.4pp (needs >4.0% for momentum thesis). AM_20 at -6.5% indicates price below own 20MA trend. Underperforming sector by 5.0pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.33x) but short-term weakness (below SMA20). MACD histogram bearish (-8.30), momentum weakening. Elevated volume (1.4x 20MA), institutional activity likely.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -8.44% (CS: 3) | Weak |
| RSI_14 | 37.1 | Neutral |
| MACD Histogram | -8.30 | Bearish |
| vs SMA20 | 0.935x | Below |
| vs SMA50 | 0.969x | Below |
| vs SMA200 | 1.334x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $549.17
- **Stop Loss:** $512.35 (6.7% risk)
- **Target:** $585.99 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 13
- **Position Value:** $7,139.21
- **Portfolio %:** 7.14%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-09 (Est: $4.21)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.57 | $3.86 | +8.1% |
| 2025Q2 | $3.00 | $3.10 | +3.5% |
| 2025Q1 | $3.07 | $3.67 | +19.6% |
| 2024Q4 | $3.12 | $3.68 | +18.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*